Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Interest Expenses of $3.5 million for Q1 2026, up 529.45% year-over-year from $550000.0 in Q1 2025, and down 3.46% quarter-over-quarter from $3.6 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Interest Expenses history runs 14 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 529.45% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $8.2 million (up 383.58% YoY), while the FY2025 annual figure was $316.8 million, up 51.95% from the prior year.
- Interest Expenses for Q1 2026 stood at $3.5 million, down from $3.6 million in the prior quarter.
- The five-year high for Interest Expenses was $15.5 million in Q3 2024, with the low at -$7000.0 in Q4 2022.
- The 5-year median for Interest Expenses is $555000.0 (2025), against an average of $2.0 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses slumped 103.5% in 2022, then jumped 5814.29% in 2023.
- Viridian Therapeutics, Inc.\DE's Interest Expenses stood at -$7000.0 in 2022, then surged by 5814.29% to $400000.0 in 2023, then tumbled by 65.0% to $140000.0 in 2024, then surged by 2461.43% to $3.6 million in 2025, then slipped by 3.46% to $3.5 million in 2026.
- Business Quant data shows VRDN's Interest Expenses at $3.5 million in Q1 2026, $3.6 million in Q4 2025, and $560000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 43.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.02 Mn |
| Jun 30, 2026 | 43.02 Mn |
| Mar 31, 2026 | 3.46 Mn |
| Mar 31, 2026 | 3.46 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 560,000.00 |
| Sep 30, 2025 | 560,000.00 |
| Jun 30, 2025 | 4.72 Mn |
| Jun 30, 2025 | 4.72 Mn |
| Mar 31, 2025 | 550,000.00 |
| Mar 31, 2025 | 550,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 15.52 Mn |
| Sep 30, 2024 | 15.52 Mn |
| Jun 30, 2024 | 597,000.00 |
| Jun 30, 2024 | 597,000.00 |
| Mar 31, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.09 Mn |